Indications And Usage

Prevention nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12.

Aprepitant 125 mg/80 mg is given as part of combination therapy

Administration

The hard capsule should be swallowed whole. Aprepitant may be taken with or without food

Contraindications

Hypersensitivity to the active substance or to any of the excipients. with pimozide, terfenadine, astemizole or cisapride.

Precautions

Aprepitant should be used with caution in patients receiving concomitant orally administered active substances that are metabolised primarily through CYP3A4 and with a narrow therapeutic range, such as cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, ergot alkaloid derivatives, fentanyl, and quinidine Additionally, concomitant administration with irinotecan should be approached with particular caution as the combination might result in increased toxicity.

Adverse Reactions

Tiredness, hiccups, nausea, vomiting, heartburn, stomach pain, diarrhea, constipation, loss of appetite, hair loss, headache, dizziness, mild skin rash, ringing in your ears, sleep problems (insomnia).

Pregnancy and lactation

For aprepitant no clinical data on exposed pregnancies are available

aprepitant should not be used during pregnancy unless clearly necessary.

Renal and liver Impairment

There are limited data in patients with moderate hepatic impairment and no data in patients with severe hepatic impairment. Aprepitant should be used with caution in these patients

Laboratory Tests